Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | ADH1B | P00325 | 2/20 | 0.31 |
| ▸ | ADH1C | P00326 | 2/20 | 0.31 |
| ▸ | ADH1A | P07327 | 2/20 | 0.31 |
| ▸ | ADH4 | P08319 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ADH7 | P40394 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11909720 | 1.00 | NPC1 (0.38) | NPC1CA1CA2ADH1BADH1C | |
| SCHEMBL9035182 | 1.00 | NPC1 (0.38) | NPC1CA1CA2ADH1BADH1C | |
| SCHEMBL6987461 | 0.98 | NPC1 (0.34) | NPC1 | |
| SCHEMBL9036075 | 0.88 | — | — | |
| SCHEMBL4952178 | 0.82 | NPC1 (0.34) | NPC1HPGD | |
| SCHEMBL73235 | 0.80 | NPC1 (0.45) | NPC1CA1CA2ADH1BADH1C | |
| SCHEMBL8802672 | 0.80 | NPC1 (0.45) | NPC1CA1CA2ADH1BADH1C | |
| SCHEMBL25700953 | 0.78 | SLC6A2 (0.33) | — | |
| SCHEMBL112607 | 0.78 | — | — | |
| SCHEMBL9517342 | 0.77 | NPC1 (0.48) | NPC1CA1CA2HPGDEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 935 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0915843-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSES | SMITHKLINE BEECHAM PLC (GB) | 1999-05-19 | — | — | EP | claimed |
| WO-1997041098-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1997-11-06 | — | — | WO | claimed |
| EP-3365334-B1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-20240199543-A1 | Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2024-06-20 | — | — | US | disclosed |
| US-20240197679-A1 | NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS | Altrartis Therapeutics Inc. | 2024-06-20 | — | — | US | disclosed |
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2024-06-20 | — | — | US | disclosed |
| EP-4370114-A2 | NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS | Mydecine Innovations Group Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20240158443-A1 | Compositions And Methods of Synthesizing Shape Shifting Cyclic Peptides (Sscp) And Their Use in The Identification of Novel Therapeutic Compounds | UNIV COLORADO REGENTS (US) | 2024-05-16 | — | — | US | disclosed |
| US-11952342-B2 | Aza-substituted psilocin analogs and methods of synthesizing the same | MYDECINE INNOVATIONS GROUP INC. (US) | 2024-04-09 | — | — | US | disclosed |
| CN-117813121-A | Biphosphine compounds and complexes | 癌症研究技术有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20240101513-A1 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | MYDECINE INNOVATIONS GROUP INC. | 2024-03-28 | — | — | US | disclosed |
| US-6107299-A | INSECTICIDES; MITICIDES | HOECHST SCHERING AGREVO GMBH (DE) | 2000-08-22 | — | — | US | disclosed |
| WO-2000010980-A1 | PYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2000-03-02 | — | — | WO | disclosed |
| WO-1999059979-A1 | SUBSTITUTED PYRIDINE AND PYRIMIDINES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PESTICIDES | AVENTIS CROPSCIENCE GMBH (DE) | 1999-11-25 | — | — | WO | disclosed |
| WO-1999059978-A1 | SUBSTITUTED NITROGEN HETEROCYCLES AND THEIR USE AS PESTICIDES | AVENTIS CROPSCIENCE GMBH (DE) | 1999-11-25 | — | — | WO | disclosed |
| EP-0915843-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSES | SMITHKLINE BEECHAM PLC (GB) | 1999-05-19 | — | — | EP | disclosed |
| US-5859009-A | Substituted spiroalkylamino and alkoxy heterocycles, processes for their preparation, and their use as pesticides and fungicides | HOECHST SCHERING AGREVO GMBH (DE) | 1999-01-12 | — | — | US | disclosed |
| EP-0869943-A1 | MONOCYCLIC BETA-LACTAME DERIVATIVES FOR TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997041098-A1 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1997-11-06 | — | — | WO | disclosed |
| WO-1997021675-A1 | MONOCYCLIC BETA-LACTAME DERIVATIVES FOR TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 1997-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101513-A1 | Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | TOP2A, PAICS, TOP1 | NPC1 350/4885CA1 4236/4885CA2 4873/4885 |
| US-20240197679-A1 | NOVEL SHORT-ACTING PSYCHOACTIVE COMPOUNDS OF THE MDMA CLASS | PNMT, HTR2C, SLC18A2 | NPC1 3067/4885CA1 4486/4885CA2 4803/4885 |
| US-11952342-B2 | Aza-substituted psilocin analogs and methods of synthesizing the same | TOP2A, PAICS, TOP1 | NPC1 558/4885CA1 4057/4885CA2 4859/4885 |
| US-20240158443-A1 | Compositions And Methods of Synthesizing Shape Shifting Cyclic Peptides (Sscp) And Their Use in The Identification of Novel Therapeutic Compounds | VIP, PTMS, QPCT | NPC1 4746/4885CA1 1589/4885CA2 1206/4885 |
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | NPC1 1060/4885CA1 2764/4885CA2 2663/4885 |
| US-20240199543-A1 | Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same | TOP2A, PAICS, TOP1 | NPC1 558/4885CA1 4057/4885CA2 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.